Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins

Journal of Biological Chemistry

Volumn 288, Issue 34, 2013, Pages 24809-24824

  Su, Shifeng ^a,b,e   Minges, John T ^a,b   Grossman, Gail ^a,b   Blackwelder, Amanda J ^a,b,f   Mohler, James L ^c,d   Wilson, Elizabeth M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^f NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN-DEPENDENT KINASE INHIBITORS; ENDOGENOUS EXPRESSION; SELECTIVE INTERACTION; TRANSCRIPTIONAL ACTIVATIONS; TRANSCRIPTIONAL ACTIVATORS; TRANSCRIPTIONAL ACTIVITY; TRANSCRIPTIONAL REPRESSION; TRANSCRIPTIONAL REPRESSORS;

ANTIGENS; CHEMICAL ACTIVATION; DERMATOLOGY; ONCOLOGY; PROTEINS; RUBIDIUM;

DISEASES;

ANDROGEN RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; E1A ASSOCIATED P300 PROTEIN; E1A PROTEIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN A11; PROTEIN P107; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CONTROLLED STUDY; DNA VECTOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN INTERACTION; PROTO ONCOGENE; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UBIQUITINATION;

ANDROGEN RECEPTOR; CELL CYCLE REGULATION; E2F TRANSCRIPTION FACTOR; GENE TRANSCRIPTION; MAGE-A11; MELANOMA ANTIGEN-A11; P107; PROSTATE CANCER; RETINOBLASTOMA (RB); STEROID RECEPTOR COREGULATOR;

ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, NEOPLASM; CERCOPITHECUS AETHIOPS; COS CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; E1A-ASSOCIATED P300 PROTEIN; E2F1 TRANSCRIPTION FACTOR; HELA CELLS; HUMANS; MALE; NEOPLASM PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN STABILITY; RECEPTORS, ANDROGEN; RETINOBLASTOMA-LIKE PROTEIN P107; TRANSCRIPTION, GENETIC;

EID: 84881013979     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.468579     Document Type: Article

References (120)

1. Bai, S., He, B., and Wilson, E. M. (2005) Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol. Cell Biol. 25, 1238-1257
2. Su, S., Blackwelder, A. J., Grossman, G., Minges, J. T., Yuan, L., Young, S. L., and Wilson, E. M. (2012) Primate-specific melanoma antigen-A11 regulates isoform-specific human progesterone receptor-B transactivation. J. Biol. Chem. 287, 34809-34824
3. Askew, E. B., Bai, S., Hnat, A. T., Minges, J. T., and Wilson, E. M. (2009) Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptorNH2-terminal transactivation domain to p160 coactivators. J. Biol. Chem. 284, 34793-34808
4. Askew, E. B., Bai, S., Blackwelder, A. J., and Wilson, E. M. (2010) Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J. Biol. Chem. 285, 21824-21836
5. He, B., Kemppainen, J. A., and Wilson, E. M. (2000) FXXLF and WXXLF sequences mediate theNH2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 275, 22986-22994
6. 2-and carboxylterminal interaction. J. Biol. Chem. 277, 25631-25639
7. 2-and carboxyl-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J. Biol. Chem. 276, 42293-42301
8. He, B., Gampe, R. T., Jr., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., Kalman, R. I., Minges, J. T., and Wilson, E. M. (2004) Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol. Cell 16, 425-438
9. Liu, Q., Su, S., Blackwelder, A. J., Minges, J. T., and Wilson, E. M. (2011) Gain in transcriptional activity by primate-specific coevolution of melanoma antigen-A11 and its interaction site in the androgen receptor. J. Biol. Chem. 286, 29951-29963
10. Minges, J. T., Su, S., Grossman, G., Blackwelder, A. J., Pop, E. A., Mohler, J. L., and Wilson, E. M. (2013) Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers. J. Biol. Chem. 288, 1939-1952
11. Wilson, E. M. (2010) Androgen receptor molecular biology and potential targets in prostate cancer. Therap. Adv. Urol. 2, 105-117
12. Bai, S., Grossman, G., Yuan, L., Lessey, B. A., French, F. S., Young, S. L., and Wilson, E. M. (2008) Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. Mol. Hum. Reprod. 14, 107-116
13. Bai, S., and Wilson, E. M. (2008) Epidermal growth factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol. Cell Biol. 28, 1947-1963
14. Karpf, A. R., Bai, S., James, S. R., Mohler, J. L., and Wilson, E. M. (2009) Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol. Cancer Res. 7, 523-535
15. Burkhart, D. L., and Sage, J. (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer 8, 671-682
16. Morris, E. J., and Dyson, N. J. (2001) Retinoblastoma protein partners. Adv. Cancer Res. 82, 1-54
17. Genovese, C., Trani, D., Caputi, M., and Claudio, P. P. (2006) Cell cycle control and beyond. Emerging roles for the retinoblastoma gene family. Oncogene 25, 5201-5209
18. Dyson, N. (1998) The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245-2262
19. Cobrinik, D. (2005) Pocket proteins and cell cycle control. Oncogene 24, 2796-2809
20. Blais, A., and Dynlacht, B. D. (2007) E2F-associated chromatin modifiers and cell cycle control. Curr. Opin. Cell Biol. 19, 658-662
21. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer. The next generation. Cell 144, 646-674
22. Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., Mc Henry, K. T., Pinchback, R. M., Ligon, A. H., Cho, Y. J., Haery, L., Greulich, H., Reich, M., Winckler, W., Lawrence, M. S., Weir, B. A., Tanaka, K. E., Chiang, D. Y., Bass, A. J., Loo, A., Hoffman, C., Prensner, J., Liefeld, T., Gao, Q., Yecies, D., Signoretti, S., Maher, E., Kaye, F. J., Sasaki, H., Tepper, J. E., Fletcher, J. A., Tabernero, J., Baselga, J., Tsao, M. S., Demichelis, F., Rubin, M. A., Janne, P. A., Daly, M. J., Nucera, C., Levine, R. L., Ebert, B. L., Gabriel, S., Rustgi, A. K., Antonescu, C. R., Ladanyi, M., Letai, A., and Garraway, L. A. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905
23. Kondo, T., Higashi, H., Nishizawa, H., Ishikawa, S., Ashizawa, S., Yamada, M., Makita, Z., Koike, T., and Hatakeyama, M. (2001) Involvement of pRB-related p107 protein in the inhibition of S phase progression in response to genotoxic stress. J. Biol. Chem. 276, 17559-17567
24. Wirt, S. E., and Sage, J. (2010) p107 in the public eye. An Rb understudy and more. Cell Div. 5, 9
25. Bellacchio, E., and Paggi, M. G. (2013) Understanding the targeting of the RB family proteins by viral oncoproteins to defeat their oncogenic machinery. J. Cell Physiol. 228, 285-291
26. Felsani, A., Mileo, A. M., and Paggi, M. G. (2006) Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25, 5277-5285
27. Fattaey, A. R., Harlow, E., and Helin, K. (1993) Independent regions of adenovirus E1A are required for binding to and dissociation of E2Fprotein complexes. Mol. Cell Biol. 13, 7267-7277
28. Ikeda, M. A., and Nevins, J. R. (1993) Identification of distinct roles for separate E1A domains in disruption of E2F complexes. Mol. Cell Biol. 13, 7029-7035
29. Liu, X., and Marmorstein, R. (2007) Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor. Genes Dev. 21, 2711-2716
30. Lubahn, D. B., Joseph, D. R., Sar, M., Tan, J., Higgs, H. N., Larson, R. E., French, F. S., and Wilson, E. M. (1988) The human androgen receptor. Complementary DNA cloning, sequence analysis and gene expression in prostate. Mol. Endocrinol. 2, 1265-1275
31. Simental, J. A., Sar, M., Lane, M. V., French, F. S., and Wilson, E. M. (1991) Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem. 266, 510-518
32. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. (1994) Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 54, 6078-6082
33. Claudio, P. P., Howard, C. M., Baldi, A., De Luca, A., Fu, Y., Condorelli, G., Sun, Y., Colburn, N., Calabretta, B., and Giordano, A. (1994) p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res. 54, 5556-5560
34. + coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. Mol. Cancer Res. 8, 183-193
35. Zhu, L., van den Heuvel, S., Helin, K., Fattaey, A., Ewen, M., Livingston, D., Dyson, N., and Harlow, E. (1993) Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev. 7, 1111-1125
36. Chen, C. R., Kang, Y., Siegel, P. M., and Massagué, J. (2002) E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression. Cell 110, 19-32
37. Huang, W., Shostak, Y., Tarr, P., Sawyers, C., and Carey, M. (1999) Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J. Biol. Chem. 274, 25756-25768
38. Johnson, D. G., Ohtani, K., and Nevins, J. R. (1994) Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8, 1514-1525
39. Cherian, M. T., Wilson, E. M., and Shapiro, D. J. (2012) A competitive inhibitor that reduces recruitment of androgen receptor to androgenresponsive genes. J. Biol. Chem. 287, 23368-23380
40. Askew, E. B., Gampe, R. T., Jr., Stanley, T. B., Faggart, J. L., and Wilson, E. M. (2007) Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J. Biol. Chem. 282, 25801-25816
41. He, B., Minges, J. T., Lee, L. W., and Wilson, E. M. (2002) The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J. Biol. Chem. 277, 10226-10235
42. Quarmby, V. E., Kemppainen, J. A., Sar, M., Lubahn, D. B., French, F. S., and Wilson, E. M. (1990) Expression of recombinant androgen receptor in cultured mammalian cells. Mol. Endocrinol. 4, 1399-1407
43. Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., and Tindall, D. J. (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469-5477
44. Sun, S., Sprenger, C. C., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., Nelson, P. S., and Plymate, S. R. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715-2730
45. Bagchi, S., Raychaudhuri, P., and Nevins, J. R. (1989) Phosphorylation-dependent activation of the adenovirus-inducible E2F transcription factor in a cell-free system. Proc. Natl. Acad. Sci. U.S.A. 86, 4352-4356
46. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massagué, J. (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66
47. Wang, C., Hou, X., Mohapatra, S., Ma, Y., Cress, W. D., Pledger, W. J., and Chen, J. (2005) Activation of p27Kip1 expression by E2F1. Anegative feedback mechanism. J. Biol. Chem. 280, 12339-12343
48. Hodul, P. J., Dong, Y., Husain, K., Pimiento, J. M., Chen, J., Zhang, A., Francois, R., Pledger, W. J., Coppola, D., Sebti, S. M., Chen, D. T., and Malafa, M. P. (2013) Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. PLoS ONE 8, e52526
49. Tsihlias, J., Kapusta, L. R., DeBoer, G., Morava-Protzner, I., Zbieranowski, I., Bhattacharya, N., Catzavelos, G. C., Klotz, L. H., and Slingerland, J. M. (1998) Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58, 542-548
50. Yang, R. M., Naitoh, J., Murphy, M., Wang, H. J., Phillipson, J., deKernion, J. B., Loda, M., and Reiter, R. E. (1998) Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159, 941-945
51. 1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J. Biol. Chem. 273, 20213-20222
52. 1 cyclin/cyclin-dependent kinase-coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression. J. Biol. Chem. 277, 50263-50274
53. Trimarchi, J. M., and Lees, J. A. (2002) Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell Biol. 3, 11-20
54. Lees, J. A., Saito, M., Vidal, M., Valentine, M., Look, T., Harlow, E., Dyson, N., and Helin, K. (1993) The retinoblastoma protein binds to a family of E2F transcription factors. Mol. Cell Biol. 13, 7813-7825
55. Chellappan, S. P., Hiebert, S., Mudryj, M., Horowitz, J. M., and Nevins, J. R. (1991) The E2F transcription factor is a cellular target for the RB protein. Cell 65, 1053-1061
56. Cao, L., Faha, B., Dembski, M., Tsai, L. H., Harlow, E., and Dyson, N. (1992) Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature 355, 176-179
57. Cobrinik, D., Whyte, P., Peeper, D. S., Jacks, T., and Weinberg, R. A. (1993) Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7, 2392-2404
58. 1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-RbhSWI/SNF and Rb-hSWI/SNF. Cell 101, 79-89
59. Rayman, J. B., Takahashi, Y., Indjeian, V. B., Dannenberg, J. H., Catchpole, S., Watson, R. J., te Riele, H., and Dynlacht, B. D. (2002) E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev. 16, 933-947
60. Strobeck, M. W., Knudsen, K. E., Fribourg, A. F., DeCristofaro, M. F., Weissman, B. E., Imbalzano, A. N., and Knudsen, E. S. (2000) BRG-1 is required for RB-mediated cell cycle arrest. Proc. Natl. Acad. Sci. U.S.A. 97, 7748-7753
61. David, G., Grandinetti, K. B., Finnerty, P. M., Simpson, N., Chu, G. C., and Depinho, R. A. (2008) Specific requirement of the chromatin modifier mSin3B in cell cycle exit and cellular differentiation. Proc. Natl. Acad. Sci. U.S.A. 105, 4168-4172
62. Weinberg, R. A. (1995) The retinoblastoma protein and cell cycle control. Cell 81, 323-330
63. Hume, A. J., and Kalejta, R. F. (2009) Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div. 4, 1
64. Graña, X., Garriga, J., and Mayol, X. (1998) Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 17, 3365-3383
65. Nevins, J. R. (1998) Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. 9, 585-593
66. 1 cyclinassociated kinases. Proc. Natl. Acad. Sci. U.S.A. 93, 4633-4637
67. 1 cyclin complexes. Genes Dev. 9, 1340-1353
68. Doyle, J. M., Gao, J., Wang, J., Yang, M., and Potts, P. R. (2010) MAGERING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell 39, 963-974
69. Lu, J., and Danielsen, M. (1998) Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein. J. Biol. Chem. 273, 31528-31533
70. Sharma, A., Yeow, W. S., Ertel, A., Coleman, I., Clegg, N., Thangavel, C., Morrissey, C., Zhang, X., Comstock, C. E., Witkiewicz, A. K., Gomella, L., Knudsen, E. S., Nelson, P. S., and Knudsen, K. E. (2010) The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J. Clin. Invest. 120, 4478-4492
71. Yeh, S., Miyamoto, H., Nishimura, K., Kang, H., Ludlow, J., Hsiao, P., Wang, C., Su, C., and Chang, C. (1998) Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochem. Biophys. Res. Commun. 248, 361-367
72. Xu, X., Bieda, M., Jin, V. X., Rabinovich, A., Oberley, M. J., Green, R., and Farnham, P. J. (2007)Acomprehensive ChIP-chip analysis of E2F1, E2F4, and E2F6 in normal and tumor cells reveals interchangeable roles of E2F family members. Genome Res. 17, 1550-1561
73. Attwooll, C., Lazzerini Denchi, E., and Helin, K. (2004) The E2F family. Specific functions and overlapping interests. EMBO J. 23, 4709-4716
74. Freedman, J. A., Chang, J. T., Jakoi, L., and Nevins, J. R. (2009) A combinatorial mechanism for determining the specificity of E2F activation and repression. Oncogene 28, 2873-2881
75. Hiebert, S. W., Chellappan, S. P., Horowitz, J. M., and Nevins, J. R. (1992) The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 6, 177-185
76. Schwarz, J. K., Devoto, S. H., Smith, E. J., Chellappan, S. P., Jakoi, L., and Nevins, J. R. (1993) Interactions of the p107 and Rb proteins with E2F during the cell proliferation response. EMBO J. 12, 1013-1020
77. Bandara, L. R., Lam, E. W., Sørensen, T. S., Zamanian, M., Girling, R., and La Thangue, N. B. (1994) DP-1. A cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. EMBO J. 13, 3104-3114
78. DeGregori, J., Leone, G., Miron, A., Jakoi, L., and Nevins, J. R. (1997) Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 94, 7245-7250
79. Hallstrom, T. C., and Nevins, J. R. (2009) Balancing the decision of cell proliferation and cell fate. Cell Cycle 8, 532-535
80. Slansky, J. E., Li, Y., Kaelin, W. G., and Farnham, P. J. (1993) A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol. Cell Biol. 13, 1610-1618
81. Dyson, N., Dembski, M., Fattaey, A., Ngwu, C., Ewen, M., and Helin, K. (1993) Analysis of p107-associated proteins. p107 associates with a form of E2F that differs from pRB-associated E2F-1. J. Virol. 67, 7641-7647
82. Beijersbergen, R. L., Kerkhoven, R. M., Zhu, L., Carlée, L., Voorhoeve, P. M., and Bernards, R. (1994) E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev. 8, 2680-2690
83. Takahashi, Y., Rayman, J. B., and Dynlacht, B. D. (2000) Analysis of promoter binding by the E2F and pRB families in vivo. Distinct E2F proteins mediate activation and repression. Genes Dev. 14, 804-816
84. Verona, R., Moberg, K., Estes, S., Starz, M., Vernon, J. P., and Lees, J. A. (1997) E2F activity is regulated by cell cycle-dependent changes in subcellular localization. Mol. Cell Biol. 17, 7268-7282
85. Puri, P. L., Cimino, L., Fulco, M., Zimmerman, C., La Thangue, N. B., Giordano, A., Graessmann, A., and Levrero, M. (1998) Regulation of E2F4 mitogenic activity during terminal differentiation by its heterodimerization partners for nuclear translocation. Cancer Res. 58, 1325-1331
86. Moberg, K., Starz, M. A., and Lees, J. A. (1996) E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol. Cell Biol. 16, 1436-1449
87. Ginsberg, D., Vairo, G., Chittenden, T., Xiao, Z. X., Xu, G., Wydner, K. L., DeCaprio, J. A., Lawrence, J. B., and Livingston, D. M. (1994) E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev. 8, 2665-2679
88. Rubin, S. M., Gall, A. L., Zheng, N., and Pavletich, N. P. (2005) Structure of the Rb C-terminal domain bound to E2F1-DP1. A mechanism for phosphorylation-induced E2F release. Cell 123, 1093-1106
89. Lin, W. C., Lin, F. T., and Nevins, J. R. (2001) Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 15, 1833-1844
90. Stevens, C., Smith, L., and La Thangue, N. B. (2003) Chk2 activates E2F-1 in response to DNA damage. Nat. Cell Biol. 5, 401-409
91. Yang, X. H., and Sladek, T. L. (1997) Novel phosphorylated forms of E2F-1 transcription factor bind to the retinoblastoma protein in cells overexpressing an E2F-1 cDNA. Biochem. Biophys. Res. Commun. 232, 336-339
92. Jay, P., Rougeulle, C., Massacrier, A., Moncla, A., Mattei, M. G., Malzac, P., Roëckel, N., Taviaux, S., Lefranc, J. L., Cau, P., Berta, P., Lalande, M., and Muscatelli, F. (1997) The human necdin gene, NDN, is maternally imprinted and located in the Prader-Willi syndrome chromosomal region. Nat. Genet. 17, 357-361
93. Taniura, H., Taniguchi, N., Hara, M., and Yoshikawa, K. (1998) Necdin, a postmitotic neuron-specific growth suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1. J. Biol. Chem. 273, 720-728
94. Kuwako, K., Taniura, H., and Yoshikawa, K. (2004) Necdin-related MAGE proteins differentially interact with the E2F1 transcription factor and the p75 neurotrophin receptor. J. Biol. Chem. 279, 1703-1712
95. Altintas, D. M., Shukla, M. S., Goutte-Gattat, D., Angelov, D., Rouault, J. P., Dimitrov, S., and Samarut, J. (2012) Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells. Mol. Endocrinol. 26, 1531-1541
96. Li, Y., Zhang, D. Y., Ren, Q., Ye, F., Zhao, X., Daniels, G., Wu, X., Dynlacht, B., and Lee, P. (2012) Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching. Mol. Cell Biol. 32, 2454-2466
97. Mallik, I., Davila, M., Tapia, T., Schanen, B., and Chakrabarti, R. (2008) Androgen regulates Cdc6 transcription through interactions between androgen receptor and E2F transcription factor in prostate cancer cells. Biochim. Biophys. Acta 1783, 1737-7144
98. Harlow, E., Whyte, P., Franza, B. R. Jr., and Schley, C. (1986) Association of adenovirus early-region 1A proteins with cellular polypeptides. Mol. Cell Biol. 6, 1579-1589
99. Dyson, N., Buchkovich, K., Whyte, P., and Harlow, E. (1989) The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell 58, 249-255
100. Ewen, M. E., Xing, Y. G., Lawrence, J. B., and Livingston, D. M. (1991) Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 66, 1155-1164
101. Arany, Z., Newsome, D., Oldread, E., Livingston, D. M., and Eckner, R. (1995) A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 374, 81-84
102. Rasti, M., Grand, R. J., Mymryk, J. S., Gallimore, P. H., and Turnell, A. S. (2005) Recruitment of CBP/p300, TATA-binding protein, and S8 to distinct regions at the N terminus of adenovirus E1A. J. Virol. 79, 5594-5605
103. Whyte, P., Williamson, N. M., and Harlow, E. (1989) Cellular targets for transformation by the adenovirus E1A proteins. Cell 56, 67-75
104. Ben-Israel, H., and Kleinberger, T. (2002) Adenovirus and cell cycle control. Front. Biosci. 7, 1369-1395
105. Alevizopoulos, K., Sanchez, B., and Amati, B. (2000) Conserved region 2 of adenovirus E1A has a function distinct from pRb binding required to prevent cell cycle arrest by p16INK4a or p27Kip1. Oncogene 19, 2067-2074
106. Eckner, R., Ewen, M. E., Newsome, D., Gerdes, M., DeCaprio, J. A., Lawrence, J. B., and Livingston, D. M. (1994) Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 8, 869-884
107. Fera, D., and Marmorstein, R. (2012) Different regions of the HPV-E7 and Ad-E1A viral oncoproteins bind competitively but through distinct mechanisms to the CH1 transactivation domain of p300. Biochemistry 51, 9524-9534
108. Ferrari, R., Pellegrini, M., Horwitz, G. A., Xie, W., Berk, A. J., and Kurdistani, S. K. (2008) Epigenetic reprogramming by adenovirus e1a. Science 321, 1086-1088
109. Ferguson, B., Krippl, B., Andrisani, O., Jones, N., Westphal, H., and Rosenberg, M. (1985) E1A 13S and 12S mRNA products made in Escherichia coli both function as nucleus-localized transcription activators but do not directly bind DNA. Mol. Cell Biol. 5, 2653-2661
110. Davis, J. N., Wojno, K. J., Daignault, S., Hofer, M. D., Kuefer, R., Rubin, M. A., and Day, M. L. (2006) Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 66, 11897-11906
111. Foster, C. S., Falconer, A., Dodson, A. R., Norman, A. R., Dennis, N., Fletcher, A., Southgate, C., Dowe, A., Dearnaley, D., Jhavar, S., Eeles, R., Feber, A., and Cooper, C. S. (2004) Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23, 5871-5879
112. James, S. R., Cedeno, C., Sharma, A., Zhang, W., Mohler, J. L., Odunsi, K., Wilson, E. M., and Karpf, A. R. (2013)DNAmethylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics 8, 849-863
113. Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., and Sawyers, C. L. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39
114. Gregory, C. W., Johnson, R. T., Jr., Mohler, J. L., French, F. S., and Wilson, E. M. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892-2898
115. Fang, Z., Zhang, T., Dizeyi, N., Chen, S., Wang, H., Swanson, K. D., Cai, C., Balk, S. P., and Yuan, X. (2012) Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. J. Biol. Chem. 287, 2090-2098
116. Besson, A., Dowdy, S. F., and Roberts, J. M. (2008) CDK inhibitors. Cell cycle regulators and beyond. Dev. Cell 14, 159-169
117. Chu, I. M., Hengst, L., and Slingerland, J. M. (2008) The Cdk inhibitor p27 in human cancer. Prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8, 253-267
118. 1 arrest by high dose 5 α-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19, 670-679
119. Hofman, K., Swinnen, J. V., Verhoeven, G., and Heyns, W. (2001) E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem. Biophys. Res. Commun. 283, 97-101
120. Yuan, X., Li, T., Wang, H., Zhang, T., Barua, M., Borgesi, R. A., Bubley, G. J., Lu, M. L., and Balk, S. P. (2006) Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am. J. Pathol. 169, 682-696